Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Felicia Rodrigues-Fortes"'
Autor:
Marc Terrones, Christophe Deben, Felicia Rodrigues-Fortes, Anne Schepers, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Introduction The study of resistance-causing mutations in oncogene-driven tumors is fundamental to guide clinical decisions. Several point mutations affecting the ROS1 kinase domain have been identified in the clinical setting, but their imp
Externí odkaz:
https://doaj.org/article/8badfa4b346b46089af6735007b9b043
Autor:
Christophe Deben, Edgar Cardenas De La Hoz, Felicia Rodrigues Fortes, Maxim Le Compte, Sofie Seghers, Steve Vanlanduit, Hendrik Vercammen, Bert Van Den Bogert, Nelson Dusetti, Abraham Lin, Geert Roeyen, Marc Peeters, Hans Prenen, Filip Lardon, Evelien Smits
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-11 (2024)
Abstract This study focuses on refining growth-rate-based drug response metrics for patient-derived tumor organoid screening using brightfield live-cell imaging. Traditional metrics like Normalized Growth Rate Inhibition (GR) and Normalized Drug Resp
Externí odkaz:
https://doaj.org/article/ccaa7af0afca4fca9dfbdb7f33073087
Autor:
Maxim Le Compte, Edgar Cardenas De La Hoz, Sofía Peeters, Felicia Rodrigues Fortes, Christophe Hermans, Andreas Domen, Evelien Smits, Filip Lardon, Timon Vandamme, Abraham Lin, Steve Vanlanduit, Geert Roeyen, Steven Van Laere, Hans Prenen, Marc Peeters, Christophe Deben
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, characterized by a treatment-resistant and invasive nature. In-line with these inherent aggressive characteristics, only a subset of patients show a clinical response to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::773131cd98b72c4ad27e15cd6bc1cc03
https://doi.org/10.1101/2023.02.27.530080
https://doi.org/10.1101/2023.02.27.530080
Autor:
Christophe Deben, Laurie Freire Boullosa, Felicia Rodrigues Fortes, Edgar Cardenas De La Hoz, Maxim Le Compte, Sofie Seghers, Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, Paul Van Schil, Jeroen M. H. Hendriks, Hans Prenen, Geert Roeyen, Filip Lardon, Evelien Smits
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-15 (2024)
Abstract Background This study explores the repurposing of Auranofin (AF), an anti-rheumatic drug, for treating non-small cell lung cancer (NSCLC) adenocarcinoma and pancreatic ductal adenocarcinoma (PDAC). Drug repurposing in oncology offers a cost-
Externí odkaz:
https://doaj.org/article/8c03f6975c524c59adae79b1d8c7f709
Autor:
Maxim Le Compte, Edgar Cardenas De La Hoz, Sofía Peeters, Felicia Rodrigues Fortes, Christophe Hermans, Andreas Domen, Evelien Smits, Filip Lardon, Timon Vandamme, Abraham Lin, Steve Vanlanduit, Geert Roeyen, Steven Van Laere, Hans Prenen, Marc Peeters, Christophe Deben
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-14 (2023)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, characterized by a treatment-resistant and invasive nature. In line with these inherent aggressive characteristics, only a subset of patients shows a clinical respon
Externí odkaz:
https://doaj.org/article/6632e8a47737498b80b21ca813df1b57